Bradpalm1, you wrote:
<<Three things concern me about Vivus in the short-term:
1). European rollout less than spectacular
2). Production ramp-up not to take place until Q2 at the earliest
3). FDA approval of Viagra to be announced within a month (bypassed FDA review committee)>>
First, because VVUS has to sell product to the U.K. (it has no European approvals) at a lower margin, you can hardly blame them for not wanting to flood the U.K. market with product that can be sold for higher margins here. As a shareholder I wish there was NO European rollout at this time.
Second, Leland Wilson told me that they were back to full production at the original plant, and that they were producing "at risk" product in the new plant, to be shipped when MCA approval comes. Now they call "full production" 600k units per month, less than the 800k units produced in September, '97. But with a new full line operational, that means total production for Q1 should be around 2,700k units, with one third of that held til MCA approval. I call that a ramp-up.
On your third point I have no comment except to say that your predictions of a similar nature have been accurate in the past.
Please correct me if you have other information. Particularly about the "at-risk" production.
Thanks,
Zebra |
